Literature DB >> 28324275

The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.

Eugene J Pietzak1.   

Abstract

Photodynamic diagnostic technique with blue light cystoscopy (BLC) takes advantage of the preferential uptake and accumulation of protoporphyrins in neoplastic tissue which emit a red fluorescence when illuminated with blue light (360-450 nm wavelengths). This allows enhanced visualization of small papillary tumors and flat carcinoma in situ lesions that might have been missed on white light cystoscopy (WLC). There is compelling evidence that the ability of BLC to detect these additional tumors translates into improved recurrence rates compared to WLC. However, the impact of BLC with regard to progression rates and in patients who are managed with intravesical therapy is not yet known. Further work is required to optimize the integration of BLC into clinical practice, but the future for BLC appears promising.

Entities:  

Keywords:  Blue light cystoscopy; Cysview; Hexaminolevulinate; Non-muscle invasive bladder cancer (NMIBC); Photodynamic diagnostics; Transurethral resection of bladder tumor (TURBT)

Mesh:

Substances:

Year:  2017        PMID: 28324275     DOI: 10.1007/s11934-017-0685-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  33 in total

1.  Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.

Authors:  J Alfred Witjes; Leonard G Gomella; Arnulf Stenzl; Sam S Chang; Dirk Zaak; H Barton Grossman
Journal:  Urology       Date:  2014-04-24       Impact factor: 2.649

2.  Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.

Authors:  Jonathan P Jarow; Seth P Lerner; Paul G Kluetz; Ke Liu; Rajeshwari Sridhara; Dean Bajorin; Sam Chang; Colin P N Dinney; Susan Groshen; Ronald A Morton; Michael O'Donnell; Diane Zipursky Quale; Mark Schoenberg; John Seigne; Bhadrasain Vikram
Journal:  Urology       Date:  2013-12-12       Impact factor: 2.649

3.  Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.

Authors:  Timothy O'Brien; Eleanor Ray; Kathryn Chatterton; Muhammad Shamim Khan; Ashish Chandra; Kay Thomas
Journal:  BJU Int       Date:  2013-12       Impact factor: 5.588

4.  Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Authors:  Bogdan Geavlete; Razvan Multescu; Dragos Georgescu; Marian Jecu; Florin Stanescu; Petrisor Geavlete
Journal:  BJU Int       Date:  2011-06-28       Impact factor: 5.588

Review 5.  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Authors:  Michael Rink; Marko Babjuk; James W F Catto; Patrice Jichlinski; Shahrokh F Shariat; Arnulf Stenzl; Herbert Stepp; Dirk Zaak; J Alfred Witjes
Journal:  Eur Urol       Date:  2013-07-19       Impact factor: 20.096

6.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

7.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

8.  Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.

Authors:  James B Rose; Shannon Armstrong; Gregers G Hermann; Jakob Kjellberg; Per-Uno Malmström
Journal:  BJU Int       Date:  2015-10-29       Impact factor: 5.588

9.  The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis.

Authors:  Ashish M Kamat; Michael Cookson; J Alfred Witjes; Arnulf Stenzl; H Barton Grossman
Journal:  Bladder Cancer       Date:  2016-04-27

10.  Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.

Authors:  Thorsten Bach; Patrick J Bastian; Andreas Blana; Angelika Kaminsky; Stefan Keller; Thomas Knoll; Christoph Lang; Soeren Promnitz; Burkhard Ubrig; Thomas Keller; Bryan Qvick; Maximilian Burger
Journal:  World J Urol       Date:  2016-08-30       Impact factor: 4.226

View more
  3 in total

1.  Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.

Authors:  Aayush Aayush; Saloni Darji; Deepika Dhawan; Alexander Enstrom; Meaghan M Broman; Muhammad T Idrees; Hristos Kaimakliotis; Timothy Ratliff; Deborah Knapp; David Thompson
Journal:  Oncotarget       Date:  2022-09-06

2.  The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer.

Authors:  Ellen M Cahill; Kevin Chua; Sai Krishnaraya Doppalapudi; Saum Ghodoussipour
Journal:  Curr Urol       Date:  2022-08-27

3.  Mex3a expression and survival analysis of bladder urothelial carcinoma.

Authors:  Jing-Wen Shi; Ying Huang
Journal:  Oncotarget       Date:  2017-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.